Abstract
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of
NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and
Epileptic Encephalopathy Syndrome (SCN8A-DEE).
